<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03107455</url>
  </required_header>
  <id_info>
    <org_study_id>EREMMI</org_study_id>
    <nct_id>NCT03107455</nct_id>
  </id_info>
  <brief_title>MitraClip in Acute Mitral Regurgitation</brief_title>
  <official_title>European Registry of MitraClip in Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Investigación Sanitaria en León</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Investigación Sanitaria en León</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute MR may develop in the setting of an acute myocardial infarction (AMI) as a result of
      papillary muscle dysfunction or rupture, and these patients are grossly underrepresented in
      MitraClip registries. Our group has recently published the Spanish experience with MitraClip
      in acute MI, but only 5 patients could be collected. However, the results of our initial
      experience are highly encouraging since patients performed well in such life-threatening
      condition. In order to expand the information of the device in this condition, our aim is to
      start a multinational registry in Europe.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite primary end point</measure>
    <time_frame>6 month</time_frame>
    <description>death from cardiac causes, readmission due to heart failure and mitral regurgitation &gt;2+</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Acute Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MitraClip</intervention_name>
    <description>MitraClip consists in two clip arms and opposing grippers, which can be opened and closed against each other in order to grasp and gain cooptation of MV leaflets at the origin of the regurgitant jet</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients experiencing transmural myocardial infarction in the previous 4 weeks and
        developing secondary mitral regurgitation not responding to medical therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient ≥ 18 year-old

          -  Transmural myocardial infarction in the previous 4 weeks (managed under current
             guideline's recommendations).

          -  Symptomatic severe mitral regurgitation diagnosed by left ventriculography,
             transthoracic echo or trans-oesophageal echo. Symptoms may vary form heart failure to
             cardiogenic shock.

          -  Symptoms should be stabilized by medical management: iv diuretics, inotropic support,
             LV assistance devices

          -  Considered by heart team at high risk for conventional surgery

        Exclusion Criteria:

          -  Anatomy not suitable for MitraClip implantation

          -  Technical contraindication for access to left atrium

          -  Patient candidate for emergent heart transplant

          -  Uncontrolled infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo Estevez-Loureiro, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Leon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmelo Grasso, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ferraroto Hospital Catania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Van der Heijden, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Antonius Ziekenhuis</affiliation>
  </overall_official>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Investigación Sanitaria en León</investigator_affiliation>
    <investigator_full_name>Armando Perez de Prado</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>MitraClip</keyword>
  <keyword>Acute mitral regurgitation</keyword>
  <keyword>Acute myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

